An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
Moderna's vaccine is custom-built based on an analysis of a patient's tumors after surgical removal. The vaccines are designed to train the immune system to recognize and attack specific mutations in cancer cells.
There was little difference in response rates among people whose tumors had a lot of mutations - a typical predictor of immunotherapy response - and those whose tumors did not. Merck said the companies are in talks with U.S. regulators about design of a late-stage trial, which is likely needed for approval of the combination regimen.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Merck in late-stage talks to acquire Prometheus Biosciences -WSJMerck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.
続きを読む »
Merck to buy Prometheus Biosciences for about $11 blnMerck & Co has agreed to acquire Prometheus Biosciences Inc for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
続きを読む »
Merck in talks to acquire Prometheus Biosciences: reportMerck is reportedly in talks to buy the San Diego-based Prometheus Biosciences in a promising deal that could be announced as early as Sunday.
続きを読む »
Merck to buy Prometheus Biosciences for about $11 billionMerck has agreed to acquire Prometheus Biosciences for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
続きを読む »
MindMed stock jumps 4.5% after psychedelics company reports positive findings in trial of LSD as treatment for major depressive disorderThe stock of psychedelics company Mind Medicine Inc. rose 4% Friday, after the company’s Swiss research partners reported positive results from a Phase 2...
続きを読む »
Citigroup beats estimates on higher income from loans; shares riseCitigroup Inc's first-quarter profit beat Wall Street expectations as it earned more from borrowers paying higher interest on loans.
続きを読む »